DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Faslpr/lpr mice in vivo by Lenert, Petar et al.
Open Access
Available online http://arthritis-research.com/content/11/3/R79
Page 1 of 16
(page number not for citation purposes)
Vol 11 No 3 Research article
DNA-like class R inhibitory oligonucleotides (INH-ODNs) 
preferentially block autoantigen-induced B-cell and dendritic cell 
activation in vitro and autoantibody production in lupus-prone 
MRL-Faslpr/lpr mice in vivo
Petar Lenert1, Kei Yasuda2, Liliana Busconi2, Patrice Nelson2, Courtney Fleenor1, 
Radhika S Ratnabalasuriar1, Peter L Nagy1, Robert F Ashman1, Ian R Rifkin2 and Ann Marshak-
Rothstein2
1Departments of Internal Medicine and Pathology, Carver College of Medicine, The University of Iowa, Iowa City, C312GH, 200 Hawkins Drive, IA 
52242, USA
2Departments of Microbiology and Medicine, Boston University School of Medicine, Boston, 715 Albany Street, MA 02118, USA
Corresponding author: Petar Lenert, petar-lenert@uiowa.edu
Received: 5 Feb 2009 Revisions requested: 13 Mar 2009 Revisions received: 26 Mar 2009 Accepted: 28 May 2009 Published: 28 May 2009
Arthritis Research & Therapy 2009, 11:R79 (doi:10.1186/ar2710)
This article is online at: http://arthritis-research.com/content/11/3/R79
© 2009 Lenert et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction B cells have many different roles in systemic lupus
erythematosus (SLE), ranging from autoantigen recognition and
processing to effector functions (for example, autoantibody and
cytokine secretion). Recent studies have shown that intracellular
nucleic acid-sensing receptors, Toll-like receptor (TLR) 7 and
TLR9, play an important role in the pathogenesis of SLE. Dual
engagement of rheumatoid factor-specific AM14 B cells
through the B-cell receptor (BCR) and TLR7/9 results in marked
proliferation of autoimmune B cells. Thus, strategies to
preferentially block innate activation through TLRs in
autoimmune B cells may be preferred over non-selective B-cell
depletion.
Methods We have developed a new generation of DNA-like
compounds named class R inhibitory oligonucleotides (INH-
ODNs). We tested their effectiveness in autoimmune B cells
and interferon-alpha-producing dendritic cells in vitro and in
lupus-prone MRL-Faslpr/lpr mice in vivo.
Results Class R INH-ODNs have 10- to 30-fold higher inhibitory
potency when autoreactive B cells are synergistically activated
through the BCR and associated TLR7 or 9 than when
stimulation occurs via non-BCR-engaged TLR7/9. Inhibition of
TLR9 requires the presence of both CCT and GGG triplets in
an INH-ODN, whereas the inhibition of the TLR7 pathway
appears to be sequence-independent but dependent on the
phosphorothioate backbone. This difference was also observed
in the MRL-Faslpr/lpr mice in vivo, where the prototypic class R
INH-ODN was more effective in curtailing abnormal
autoantibody secretion and prolonging survival.
Conclusions The increased potency of class R INH-ODNs for
autoreactive B cells and dendritic cells may be beneficial for
lupus patients by providing pathway-specific inhibition yet
allowing them to generate protective immune response when
needed.
Introduction
Nucleic acids, including self DNA and RNA, are recognized by
a subset of Toll-like receptors (TLRs) [1-4]. To discriminate
between self and non-self nucleic acids, the nucleic acid-sens-
ing TLRs 3, 7, 8, and 9 are expressed only within the cell inte-
rior, contrasting with other TLRs (for example, TLR2 or TLR4)
that are expressed on cell surfaces. Upon ligand entry into the
cell, TLR9 migrates from the endoplasmic reticulum to CpG-
DNA-containing endosomes [5,6]. Interestingly, the type of
endosomal compartment to which TLR9 relocates depends
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on cell type and the nature of the TLR ligand used for activa-
tion. For example, in the response of human dendritic cells
(DCs) to linear CpG-DNA, TLR9 activation goes through late
LAMP-1-positive endosomes [7,8]. In contrast, stimulation
with complex TLR9 ligands is more restricted in terms of
responding cell types and, in DCs, proceeds through early
endosomes instead. The uptake of these complex ligands may
be facilitated by CXCL16, which may influence this differential
compartmentalization [9]. Interestingly, the outcome of the DC
response to TLR9 stimulation varies greatly depending on
where TLR9 meets CpG-DNA. For example, type I interferon-
alpha (IFN-α) secretion is induced by complex class A(D)
CpG-oligonucleotides (CpG-ODNs) via early endosomal sig-
naling, whereas interleukin-6/tumor necrosis factor-alpha (IL-
6/TNF-α) secretion requires late endosomal signaling and is
induced primarily by linear TLR9 ligands [8].
Although bacterial DNA and double-stranded CpG-ODNs
stimulate macrophages vigorously, they are very poor activa-
tors of resting B cells in both humans and mice [10-13]. In
resting follicular B cells and in human naïve peripheral blood B
cells, engagement of the B-cell receptor (BCR) for antigen,
together with co-stimulation with either type I/II IFN or BAFF
(B-cell activating factor of TNF family), may prime B cells to
overcome this unresponsiveness to complex TLR ligands [13-
18]. This enhancement may be due to multiple mechanisms
(for example, TLR7 and 9 upregulation, increased ligand
uptake, BCR-mediated delivery of TLR ligands to 'autophago-
somes' where concomitant BCR and TLR signals take place,
or lowered BCR signaling threshold) [19]. It remains to be for-
mally proven whether the same type of the crosstalk between
BCR and TLR also occurs between antigen and co-delivered
TLR7 ligand.
These findings have direct implications for the pathogenesis of
systemic lupus erythematosus (SLE), a multisystemic disease
in which autoantibodies to DNA- and RNA-containing autoan-
tigens (for example, nucleosomes, Ku-autoantigen, Sm/RNP,
or splicesosomes) are the immunologic hallmark of the dis-
ease [20-22]. These antibodies frequently antedate the clini-
cal disease, and high levels of several lupus autoantibodies
nicely correlate with either specific disease subsets (for exam-
ple, lupus nephritis, congenital heart block, or subacute cuta-
neous lupus) or disease activity in general [20,23]. Immune
complexes between complement-fixing anti-double-stranded
DNA (anti-dsDNA) antibodies and corresponding autoanti-
gens are held responsible for the kidney damage in lupus
nephritis [20]. Complement levels frequently fall during major
lupus flares, further suggesting that complement-activating
immune complexes may play an important role in the tissue
pathology [20].
It was recently found that lupus autoantigens (for example,
nucleosomes or Sm/RNP) have intrinsic 'autoadjuvant' activi-
ties (endogenous mitogens) when complexed with corre-
sponding autoantibodies, causing proliferation of autoreactive
B cells and type I IFN secretion from plasmacytoid DCs [24-
32]. Depending on the nature of the initiating autoantigen, the
proliferation requires either the TLR7 or TLR9 pathway, includ-
ing the presence of the key adaptor protein MyD88 (myeloid
differentiation primary response gene 88) [25-28,33,34].
Thus, therapies aimed at blocking the TLRs may be beneficial
for treating lupus. Indeed, promising results have been
reported in animal models of lupus using TLR7- and/or TLR9-
specific antagonists [35-37].
We have recently developed a new class of inhibitory ODNs
that we named class R ('restricted') INH-ODNs [38]. We show
that these dsDNA-like analogues carrying the canonical TLR9-
inhibitory sequence [39,40] are selective for certain autoreac-
tive B cells and for type I IFN-producing DCs. They are 10- to
30-fold less potent in non-autoreactive B cells stimulated with
linear CpG-DNA ligands. In addition to autoreactive B cells,
class R INH-ODNs are capable of blocking both DNA/anti-
DNA-induced and RNA/anti-RNA-induced IFN-α secretion
from DCs. Interestingly, the latter outcome is ODN sequence-
independent but is dependent on a nuclease-resistant phos-
phorothioate (PS) backbone. Class R INH-ODNs are also
active in vivo, where they preferentially block anti-dsDNA and
anti-Sm/RNP antibody secretion and prolong survival of lupus-
prone mice. Refinement of the class R INH-ODN structure to
combine optimal TLR7/TLR9 sequences in double-stranded
carrier may result in a novel class of pathway-specific thera-
peutics for human lupus.
Materials and methods
Creating class R inhibitory ODNs for the Toll-like 
receptor-9 signaling pathway
We used INH-ODN 4084-F, with a PS backbone, as a tem-
plate for creating class R INH-ODNs (Table 1). INH-ODN
4084-F is the shortest active 12-mer INH-ODN that contains
both previously identified suppressive elements (CCT and
GGG), appropriately spaced from each other (four nucle-
otides apart) and properly oriented in a single-stranded ODN
molecule (5'-CCT → GGG-3') [39]. INH-1 was created by
adding a complementary strand of nucleotides generating a
24-mer ODN forming a complete palindrome. INH-18 is a lin-
ear 24-mer class B INH-ODN in which the 5' INH-ODN 4084-
F sequence was followed by a random stretch of 12 nucle-
otides lacking the ability to form significant secondary struc-
tures. ODNs INH-43, INH-45, and INH-47 are palindromic
variants of INH-1 in which the CCT and/or GGG elements
were replaced with random nucleotide triplets. Similarly,
ODNs INH-44, INH-46, and INH-48 are linear derivatives of
INH-18 lacking CCT, GGG, or both triplets. INH-4 and INH-
13 are palindromic or linear analogues of INH-1 and INH-18,
with the difference that the canonical CCT and GGG blocks
are placed at the 3' end of the molecule. We have further cre-
ated INH-ODNs, based on either INH-1 (for 5') or INH-4 (for
3') as templates, in which the complementary/non-CCT/Available online http://arthritis-research.com/content/11/3/R79
Page 3 of 16
(page number not for citation purposes)
GGG-containing half was truncated to create hairpin struc-
tures with short (three nucleotides), medium (six nucleotides),
or long (nine nucleotides) 5' or 3' overhangs. Shortened linear
derivatives of INH-18 and INH-13 were synthesized to serve
as controls for palindromic INH-ODNs with 3' and 5' over-
hangs. Importantly, neither the complementary sequence to
4084-F nor the random nucleotide sequence in the 3' half of
INH-18 showed any inhibitory activity on TLR9-stimulated B
cells or macrophages at concentrations as high as 1 μM (data
not shown).
Table 1
Synthetic Toll-like receptor-9 agonists and antagonists used in the study
TLR9-antagonists Class Properties
4084-F CCT GGA TGG GAA B 5' linear, shortest active
INH-1 CCT GGA TGG GAA TTC CCA TCC AGG R 5' palindrome
INH-18 CCT GGA TGG GAA CTT ACC GCT GCA B 5' linear
INH-43 CCT GGA TAA AAA TTT TTA TCC AGG R Lacks GGG
INH-44 CCT GAA TAA AAA CTT ACC GCT GCA B Lacks GGG
INH-45 TAT GGA TGG GAA TTC CCA TCC ATA R Lacks CCT
INH-46 TAT GGA TGG GAA CTT ACC GCT GCA B Lacks CCT
INH-47 TAT GGA TTT TAA TTA AAA TCC ATA R Lacks CCT/GGG
INH-48 TAT GGA TTT TAA CTT ACC GCG GCA B Lacks CCT/GGG
5' OVHG-short CCT GGA TGG GAA TTC CCA TCC R 5' short overhang
(3 nucleotide OVHG)
5' OVHG-scr. short CCT GGA TGG GAA CTT ACC GCT B 5' linear
5' OVHG-medium CCT GGA TGG GAA TTC CCA R 5' medium overhang
(6 nucleotide OVHG)
5' OVHG-scr. medium CCT GGA TGG GAA CTT ACC B 5' linear
5' OVHG-long CCT GGA TGG GAA TTC R 5' long overhang
(9 nucleotide OVHG)
5' OVHG-scr. long CCT GGA TGG GAA CTT B 5' linear
INH-4
3' palindrome
TTC CCA TCC AGG CCT GGA TGG GAA R 3' palindrome
INH-13
3' scr. pal.
CTT ACC GCT GCA CCT GGA TGG GAA B 3' linear
3' OVHG-short CCA TCC AGG CCT GGA TGG GAA R 3' short overhang
(3 nucleotide OVHG)
3' OVHG-scr. short ACC GCT GCA CCT GGA TGG GAA B 3' linear
3' OVHG-medium TCC AGG CCT GGA TGG GAA R 3' medium overhang
(6 nucleotide OVHG)
3' OVHG-scr. medium GCT GCA CCT GGA TGG GAA B 3' linear
3' OVHG-long AGG CCT GGA TGG GAA R 3' long overhang
(9 nucleotide OVHG)
3' OVHG-scr. long GCA CCT GGA TGG GAA B 3' linear
4173 RRR RRR RRR RRR RRR B Linear control, R = random
TLR9-agonists Class Properties
CpG-2336 ggGGACGACGTCGTGgggggg A(D) Lowercase PS linkages
CpG-1826 TCC ATG ACG TTC CTG ACG TT B(K) Linear, murine
CpG-2006 TCG TCG TTT TGT CGT TTT GTC GTT B(K) Linear, human
OVHG, overhang; pal., palindrome; PS, phosphorothioate; scr., scrambled; TLR, Toll-like receptor.Arthritis Research & Therapy    Vol 11 No 3    Lenert et al.
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Toll-like receptor agonists
CpG-ODNs 2336, 1826, and 2006 (Table 1) were obtained
from Coley Pharmaceuticals (Ottawa, ON, Canada). All other
ODNs were synthesized and HPLC (high-performance liquid
chromatography)-purified by Integrated DNA Technologies
(IDT) (Coralville, IA, USA) and used at concentrations of up to
1 μM (for PS-ODNs) or 30 μM (for phosphodiester [PO]-
ODNs). PS-ODNs have a PS backbone, and PO-ODNs have
a native PO backbone. TLR7/8 ligands R-837, CL-075, CL-
097, and loxoribine were purchased from InvivoGen (San
Diego, CA, USA). All reagents were endotoxin-free as deter-
mined by the Limulus amebocyte lysate assay (Pyrotell LAL
Assay; Associates of Cape Cod, Inc., East Falmouth, MA,
USA). Highly purified lipopolysaccharide (LPS) was obtained
from List Biological Laboratories, Inc. (Campbell, CA, USA).
Animal studies
MRL-MpJ-Faslpr/lpr mice were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA) and maintained under
standard conditions in the Animal Facility at The University of
Iowa. AM14 mice, expressing a BCR reactive with mouse
IgG2a, were described previously [41-43] and were bred and
maintained in microisolator cages at the Laboratory Animal
Science Center of the Boston University School of Medicine.
Several cohorts of young pre-diseased MRL-Fas lpr/lpr mice
were treated beginning from 4 weeks (rederived strain, MRL-
MpJ-Faslpr/J) or 15 weeks of age (non-rederived strain, MRL-
MpJ-Faslpr/2J). Phosphate-buffered saline (PBS), INH-1, INH-
18, INH-47, or INH-48 (1 mg/kg body weight) in a final volume
of 1 mL was injected intraperitoneally or subcutaneously three
times weekly for 12 to 25 weeks. Each experimental group
consisted of five to eight female mice. At the beginning and at
the end of the treatment protocol, blood was obtained through
retro-orbital bleeds and urine was collected. Serum was ana-
lyzed for cytokines, total immunoglobulin (Ig) levels, and
autoantibodies. Proteinuria was semi-quantified using Multistix
urinalysis strips (Bayer, Leverkusen, Germany). The study was
approved by the University of Iowa animal ethics committee,
and animals were euthanized according to Institutional Animal
Care and Use Committee procedures. Left kidney, liver, and
lungs/heart blocks were harvested and fixed in 10% buffered
formalin. Paraffin-embedded organ sections were stained with
periodic acid-Schiff and hematoxylin/eosin. The extent of kid-
ney damage was graded according to published guidelines
and scored in a blinded fashion [35]. The right kidney was
embedded in Sakura Finetek Tissue-Tek O.C.T. compound
(Sakura Finetek U.S.A., Inc., Torrance, CA, USA) and kept fro-
zen at -80°C before use in immunohistology for detection of
C3 and IgG deposits.
INH-ODN potency studies in primary macrophages, 
macrophage cell lines, and human and mouse B cells
Splenic macrophages were obtained from C57BL6 mice by
recovering the CD43+ fraction from the magnetic-activated
cell sorting (MACS) LD columns. Cells were left to adhere to
plastic for 4 hours. The adherent fraction typically contained
greater than 85% CD11b+F4/80+ cells. Experiments were
repeated with similar results using splenic macrophages
obtained by positive selection using CD11b microbeads and
two rounds of positive selection (>97% purity). For B-cell
enrichment, the pass-through CD43- MACS fraction was used
as a source of total B cells. The purity of B-cell fraction was
typically greater than 97% as judged by CD19/B220 fluores-
cence-activated cell sorting staining. The ratio between the
CD21intCD23+ follicular B cells and CD21highCD23low/- mar-
ginal zone B cells was approximately 8:1 to 15:1 in control
strains and in young (4-week-old) MRL-lpr/lpr mice. However,
with age, this ratio became substantially lower in the lupus
strain [13].
For INH-ODN potency studies, enriched primary macro-
phages, total splenic B cells, RAW264 macrophages, and the
human B-cell line (Namalwa) were incubated for 18 to 42
hours with optimal concentrations of class A(D) (100 nM),
class B(K) stimulatory CpG-ODNs (10 to 33 nM), TLR7/8 lig-
ands R-837 (1 μg/mL), or CL-075 (0.1 μg/mL) plus increasing
concentrations of INH-ODNs (from 1 to 1,000 nM). B-cell
cycle entry and protection from spontaneous apoptosis was
detected using acridine orange flow cytometry as described
previously [44]. Cell culture supernatants were collected and
tested for cytokines in enzyme-linked immunosorbent assay
(ELISA). For determination of polyclonal IgM, B cells were cul-
tured for 6 days.
DNA – or RNA- immune complex-stimulated AM14 B 
cells and dendritic cells
B cells were isolated from AM14 BCR transgenic mice by
positive selection using anti-B220-coupled magnetic beads
[17]. AM14 B cells were stimulated with the IgG2a mono-
clonal antibodies (mAbs) PL2-3, as a form of chromatin-con-
taining immune complexes [25], or BWR4 (10 μg/mL) (kindly
provided by Dan Eilat, Hadassah University Hospital, Jerusa-
lem, Israel) as a form of RNA immune complexes [28]. Results
were confirmed by stimulating AM14 B with anti-Sm antibody
Y2 (20 μg/mL final concentration) (kindly provided by Philip
Cohen and Robert Eisenberg, University of Pennsylvania, Phil-
adelphia, PA, USA) pre-mixed with purified endotoxin-free Sm/
RNP (0.628 mg/mL). For the BWR4 and Y2 studies, B cells
were pre-treated with IFN-α (PBL Laboratories) (1,000 U/mL
IFN-α for 2 to 3 hours at 37°C) to upregulate TLR7 expression,
resulting in markedly enhanced proliferation upon stimulation
with BWR4 antibodies. In some experiments, AM14 B cells
were also stimulated with linear CpG B(K) ODN-1826 (0.3
μg/mL) or ultrapure LPS (List Biological Laboratories, Inc.).
Control ODN 4173, INH-1, INH-18, and their variants were
added to cultures simultaneously with the DNA or RNA
immune complexes. Cell proliferation was measured after 24
hours by pulsing B cells for an additional 6 hours with [3H] thy-
midine. On their own, Sm/RNP particles had no activity in BAvailable online http://arthritis-research.com/content/11/3/R79
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cells. Non-transgenic B cells, in contrast to AM14 B cells,
failed to proliferate to BWR4 antibodies, whereas TLR9-defi-
cient AM14 B cells still proliferated, thus ruling out cross-reac-
tivity with DNA in culture fluids.
Bone marrow-derived DCs from Balb/c mice were cultured
with the Flt-3L for 8 days. Highly enriched DCs (3 × 104 cells
per 200 μL volumes) were additionally cultured over the
course of a 24-hour period with DNA immune complexes con-
taining CG50 (dsDNA fragment derived from the plasmid
pMCG-50 containing 50 repeats of CpG and used at 100 ng/
mL [26]) combined with PA4 IgG2a anti-dsDNA antibodies
(kindly provided by Mark Monestier, Temple University, Phila-
delphia, PA, USA) (10 μg/mL). INH-ODNs were pre-incubated
with DCs for 30 minutes before adding immune complexes. In
parallel experiments, class A(D) CpG-ODN 2336 was used
for stimulation instead (at a concentration of 300 nM). Super-
natants were collected and IFN-α measured in ELISA.
For TLR7-dependent stimulation of DCs, RNA immune com-
plexes were made by using the 05-02A antibody preparation
(SLE1) [45] from a human lupus patient at 50 μg/mL. Control
ODN, INH-1 and INH-18, and their variants lacking the CCT
and/or GGG were added to RNA/anti-RNA-stimulated DC
cultures at a concentration of 1 μg/mL. IFN-α was measured
after 24 hours.
Enzyme-linked immunosorbent assay and 
immunofluorescence studies for autoantibody detection
Serum samples from PBS- or INH-ODN-treated mice were
diluted appropriately and tested for antinuclear and anti-
dsDNA antibodies using HEp-2 or Crithidia luciliae-coated
slides, respectively (Inova Diagnostics, Inc., San Diego, CA,
USA). Bound IgG was revealed using fluorescein isothiocy-
anate-labeled anti-mouse IgG (Bethyl Laboratories, Inc., Mont-
gomery, TX, USA). Specific staining of kinetoplasts on
Crithidia slides, detected by immunofluorescence on an Olym-
pus BX-51 microscope (Olympus, Tokyo, Japan), was used as
a criterion for the presence of anti-dsDNA antibodies in lupus
sera.
Autoantibody levels against dsDNA and Sm/RNP were further
quantified by ELISA. Calf thymus Sm/nRNP antigen was pur-
chased from ImmunoVision (Springdale, AR, USA). Ultrapure
calf-thymus dsDNA was from Sigma-Aldrich (St. Louis, MO,
USA). For anti-dsDNA detection, polystyrene plates were pre-
coated with poly-L-lysine followed by S1  nuclease-treated
dsDNA (coated at 5 μg/mL). Lupus sera were diluted 1:500
and incubated on dsDNA-coated plates for 30 minutes at
room temperature. After extensive washings, bound IgG was
detected using horseradish peroxidase (HRP)-labeled anti-
mouse IgG1, IgG2a, or IgM antibodies (Bethyl Laboratories,
Inc.), respectively. A similar procedure was used for the detec-
tion of anti-Sm/RNP antibodies on plates coated with 2.5 μg/
mL Sm/nRNP.
Cytokine enzyme-linked immunosorbent assay
IL-6, TNF-α, and IL-12p40 were detected using pairs of anti-
bodies obtained from eBioscience, Inc. (San Diego, CA,
USA). For detection of type I IFN secretion [45], we used rat
anti-mouse IFN-α mAb (22100-1; PBL Biomedical Laborato-
ries, Piscataway, NJ, USA), rabbit anti-mouse IFN-α polyclonal
antibody (32100-1; PBL Biomedical Laboratories), HRP-con-
jugated donkey anti-rabbit IgG (711-036-152; Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA, USA), and
mouse r-IFN-α as a standard (12100-1; PBL Biomedical Lab-
oratories). The detection limit of the IFN-α ELISA was 80 pg/
mL.
Results
Prototypic class R and class B INH-ODNs have similar 
potencies and efficacies in macrophages and bone 
marrow-derived dendritic cells
Enriched primary macrophages from C57BL6 mice (1 × 106
per well) (Figure 1a) were stimulated with a class A(D) CpG-
ODN, with INH-ODNs added simultaneously. INH-1 (class R
INH-ODN, palindromic) and INH-18 (class B INH-ODN, linear)
were used over the concentration range shown. Cell culture
supernatants were collected after 18 hours and analyzed for
IL-12p40 (macrophages) by ELISA. Inhibition by INH-1 and
INH-18 was identical.
Bone marrow-derived Flt-3L-propagated DCs secreted IFN-α
in response to the class A(D) stimulatory CpG-ODN 2336 and
gave a smaller response to CG50/PA4 immune complexes.
Neither class of INH-ODNs nor control ODNs induced meas-
urable IFN-α secretion (Figure 1b). When added to DC cul-
tures simultaneously with TLR9 ligands, class R (INH-1) and
class B (INH-18) INH-ODNs (but not the control ODN)
showed similar inhibitory potency for TLR9 ligand-induced
IFN-α production (Figure 1c–e). Figure 1e shows the dose
response for inhibition of CG50+PA4-induced IFN-α secre-
tion.
Palindromic INH-ODNs with phosphorothioate 
backbones show 10- to 30-fold lower potency than linear 
INH-ODNs for inhibiting Toll-like receptor-9 stimulation 
of primary mouse and human B cells
We next tested the effect of these INH-ODNs on resting
mouse B cells stimulated with linear TLR9 ligands. Total
CD43- resting B cells from 6- to 8-week-old C57BL6 spleens
(composed of approximately 90% follicular B cells and approx-
imately 10% marginal zone B cells) were stimulated with linear
CpG-1826 either for 18 to 24 hours (for measuring cell cycle
entry, apoptosis protection, and IL-6 secretion) or for 6 days
(for polyclonal IgM secretion). A range of concentrations of
either class B or class R INH-ODNs were added simultane-
ously. While both INH-ODNs showed efficacy, linear class B
INH-18 was 10- to 30-fold more potent than class R INH-1,
even though different outcome assays required different con-Arthritis Research & Therapy    Vol 11 No 3    Lenert et al.
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centrations of INH-ODNs to reach the 50% inhibition point (for
example, Apo>G1-M entry>IL-6>IgM) (Figure 2a–d).
To check whether the observed difference extends to INH-
ODNs synthesized with the natural PO backbone, INH-1 and
INH-18 were made with the PO backbone. In this case, we
used a stimulatory CpG-ODN also made with the PO back-
bone at a concentration of 10 μM. Various outcomes (for
example, IL-6, G1-M entry, and IgM secretion) were measured,
and dose-dependent inhibition of IgM secretion is shown.
Again, at least a 30-fold potency difference for IgM secretion
between PO backbone versions of INH-1 and INH-18 was
observed (Figure 2e).
Similar to resting mouse B cells, the human B-cell line
Namalwa, expressing a high level of TLR9 [46], was sensitive
to inhibition with both class R and class B INH-ODNs (Figure
2f) when CD86 upregulation was measured as an outcome.
However, again class B INH-ODNs (INH-13 is shown) were
10 times more potent than class R (INH-4) (Figure 2f). Similar
results were observed in human peripheral blood B cells and
with INH-1 compared with INH-18 (data not shown).
The size of the single-stranded overhang in INH-ODNs 
with partial palindromes determines the potency 
difference between class B and class R INH-ODNs
We next created INH-ODNs with partial palindromes and sin-
gle-stranded linear segments at their 3' or 5' ends ranging
from three to nine nucleotides in length. We reasoned that the
selectivity favoring linear INH-ODNs in resting B cells may be
lost if 5'→3' or 3'→ 5' helicases are recruited to the TLR9 sig-
nalosome. As predicted, creating INH-ODNs with progres-
sively longer linear overhangs attached to their 3' or 5' ends
increased the potency of such class R INH-ODNs in TLR9-
stimulated B cells, eventually abrogating the difference
between the class B and class R INH-ODNs. Figure 3 shows
results of apoptosis protection; however, very similar data
were observed with other B-cell outcomes (for example, G1-M
entry, IL-6, and IgM secretion).
Figure 1
Class R and B inhibitory oligonucleotides (INH-ODNs) have similar inhibitory potencies for Toll-like receptor-9 (TLR9)-activated primary macro- phages and dendritic cells (DCs) Class R and B inhibitory oligonucleotides (INH-ODNs) have similar inhibitory potencies for Toll-like receptor-9 (TLR9)-activated primary macro-
phages and dendritic cells (DCs). (a) Enriched primary macrophages were stimulated with class A(D) CpG-ODN (100 nM) for 18 to 24 hours. INH-
ODNs were added over the concentration range shown. Interleukin (IL)-12p40 and tumor necrosis factor-alpha (TNF-α) were measured in enzyme-
linked immunosorbent assay (ELISA). Flt-3-propagated bone marrow-derived DCs were stimulated for 24 hours either with class A(D) CpG-ODN 
2336 or CG50+PA4 immune complexes or with various combinations of TLR9 ligands and class R or class B INH-ODNs or control ODNs. INH-
ODNs and control ODNs were used either at a concentration of 1 μg/mL (b-d) or over the concentration range shown (e). Interferon-alpha (IFN-α) 
secretion was measured in ELISA (n = 3 to 5). *P < 0.05.Available online http://arthritis-research.com/content/11/3/R79
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Class R INH-ODNs require canonical CCT and GGG 
triplets for inhibition of rheumatoid factor-specific AM14 
B cells stimulated with DNA-containing immune 
complexes
A very useful model for studying autoreactive B-cell activation,
the AM14 B cells express transgenic BCRs that recognize
IgG2a antibodies. When PL2-3 (IgG2a) anti-nucleosome anti-
bodies are added to spent cultures, AM14 B cells proliferate
in a TLR9-dependent fashion [25]. Similar to resting mouse B
cells, AM14 cells proliferate in response to linear TLR9 ligands
(CpG-1826) and this proliferation can be inhibited in a dose-
dependent fashion with class B INH-18 but not with control
ODNs (Figure 4a). Class R INH-1 is at least 10-fold less
potent than INH-18 when CpG-1826 is used for stimulation.
However, when PL2-3 antibodies are used for stimulation, the
potency of class R INH-ODNs increases 10-fold to equal that
of class B INH-ODNs (Figure 4b). Since the control ODNs
showed slight inhibitory activity, it means that added ODNs
compete with endogenous DNA either for binding to PL2-3
antibodies or for the subsequent BCR-mediated delivery to a
TLR9 signaling compartment. As a control for specificity and
to rule out non-selective toxicity of INH-ODNs, we also stimu-
lated AM14 B cells with LPS. Neither INH-ODNs nor control
ODNs could inhibit LPS-induced AM14 proliferation over the
concentration range shown in Figure 4c.
We next tested sequence requirements for inhibition in AM14
B cells. We created linear (18, 44, 46, and 48) and palindro-
mic (1, 43, 45, and 47) INH-ODNs lacking the CCT element
(45 and 46), GGG element (43 and 44), or both (47 and 48).
Similar to control ODN 4173, INH-47 and INH-48 not only
lacked the ability to block the TLR9 stimulation of AM14 B
cells induced with PL2-3-containing immune complexes but
actually co-stimulated proliferation to a certain degree (Figure
Figure 2
Class R inhibitory oligonucleotides (INH-ODNs) show lower potency for resting mouse and human B cells Class R inhibitory oligonucleotides (INH-ODNs) show lower potency for resting mouse and human B cells. Total CD43- B cells from C57BL6 mice 
were stimulated with class B(K) CpG-ODN 1826 for either 18 to 42 hours (a-c) or 6 days (d) in the presence of increasing concentrations of INH-
ODNs (1 to 1,000 nM). Percentage of cells with hypodiploid DNA content and cells entering the G1-M phase of the cell cycle was determined in 
acridine orange flow cytometry. Interleukin-6 (IL-6) and polyclonal IgM were measured in enzyme-linked immunosorbent assay (ELISA) (n = 3 to 7). 
(e) Total mouse B cells were stimulated with PO-CpG-ODN for 6 days. (f) Total human Namalwa B cells were stimulated with human PS-CpG-
2006 for 42 hours. CD86 expression and polyclonal IgM secretion were measured. Indicated class R and B INH-ODNs were added over the con-
centration range shown (n = 3 or 4). *P < 0.05. PO, phosphodiester; PS, phosphorothioate.Arthritis Research & Therapy    Vol 11 No 3    Lenert et al.
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5). The two elements were equally important for inhibition, as
observed both in class B and in class R INH-ODN variants
tested, suggesting that the requirement for both CCT and
GGG elements previously observed in non-autoreactive B
cells also applies to AM14 B cells.
INH-ODNs made with phosphorothioate backbone 
inhibit activation of dendritic cells, macrophages, and 
RNA/anti-RNA-stimulated AM14 B cells in a sequence-
independent and backbone-dependent fashion
Recent literature suggests that some TLRs may bind their lig-
ands through their sugar backbone residues and that posses-
sion of a PS backbone not only protects from nucleases but
also increases affinity for the relevant TLR [3,4]. As TLR7 has
restricted cell distribution in humans (plasmacytoid DCs and
B cells) and has been linked to lupus pathogenesis in mice
[47-49], we next tested the ability of class R and B INH-ODNs
to block TLR7-induced activation of macrophages, DCs,
AM14 B cells, and primary mouse B cells. Figures 6a and 6b
show the ability of both classes of INH-ODNs to block the acti-
vation of RAW macrophages in a dose-dependent fashion.
Fifty percent inhibition was achieved with approximately 10 to
33 nM. These results were obtained with TLR7 ligands R-837
and CL-075, respectively. Interestingly, the same level of inhi-
bition was observed with the control ODN-4173. Similar
results were observed in primary mouse macrophages (data
not shown). We next studied the effect of class R and B INH-
ODNs and their variants on TLR7 activation of bone marrow-
derived Flt-3L-propagated DCs. IFN-α secretion was meas-
ured in ELISA. When ODNs were used at a concentration of
1 μg/mL (approximately 125 nM), RNA/anti-RNA-induced IFN-
α secretion was similarly inhibited, not only by prototypic class
B and class R INH-ODNs, but also by their variants lacking
CCT and/or GGG, as well as control ODN-4173 (Figure 6c).
We further studied the effect of INH-ODNs 1 and 18 and the
control ODN 4173 on BWR4 (IgG2a) + RNA-induced prolif-
Figure 3
The size of the linear overhang determines the potency difference between class R and class B inhibitory oligonucleotides (INH-ODNs) The size of the linear overhang determines the potency difference between class R and class B inhibitory oligonucleotides (INH-ODNs). Total mouse 
B cells were stimulated with 33 nM CpG-1826 together with indicated class R or class B INH-ODNs added simultaneously and used over the con-
centration range shown. (a) Palindromic Class R INH-4 and linear INH-13 ODNs with CCT/GGG blocks at the 3' were used. (b) Palindromic Class 
R INH-1 and linear INH-18 ODNs with CCT/GGG blocks at the 5' end were used. (c) INH-ODNs with short, medium or long 3' linear overhangs or 
linear INH-ODNs of the equal length were used. (d) INH-ODNs with short, medium or long 5' linear overhangs or linear INH-ODNs of the equal 
length were used. Inhibition of CpG-1826-induced rescue from apoptosis is shown. Sequences of INH-ODNs are shown in Table 1 (n = 3 to 5). *P 
< 0.05. OVHG, overhang; scr., scrambled.Available online http://arthritis-research.com/content/11/3/R79
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eration of AM14 B cells (Figure 6d). Similarly to macrophages
and DCs, stimulation of AM14 B cells with RNA-containing
immune complexes (including immune complexes containing
the lupus autoantigen Sm/RNP and anti-Sm antibodies; data
not shown) was inhibited indiscriminately with both classes of
INH-ODNs and with control ODNs. However, in primary non-
autoreactive mouse B cells, INH-18, compared with INH-1,
was a much more potent inhibitor of the TLR7 ligand-induced
CD86 expression (Figure 6e). When INH-ODNs were made
with natural PO backbone and tested at concentrations of up
to 10 μM, neither class B nor class R INH-ODNs could inhibit
R-837-induced activation of RAW cells or IgM secretion from
primary B cells (data not shown), suggesting a PS backbone-
dependent inhibitory effect on TLR7 activation, not affected by
base sequence.
Class R INH-ODNs block anti-double-stranded DNA and 
anti-Sm/RNP secretion in vivo in lupus mice
To address whether class R INH-ODNs preferentially affect
autoreactive B cells in vivo more than normal B cells, we used
the MRL-Faslpr/lpr model of lupus. In this model, mice develop
massive lymphoproliferation (lymphadenomegaly and
splenomegaly) due to the mutation in the Fas and additionally
produce numerous autoantibodies, including anti-dsDNA and
anti-Sm/RNP [50]. Several lines of evidence suggest that
autoreactive B cells play a primary role in the pathogenesis of
SLE, not only as autoantibody secreting effector cells but as
key antigen-presenting cells [23]. When pre-diseased MRL-
Faslpr/lpr mice (2J strain) were treated with either class R or
class B INH-ODNs intraperitoneally at a dose of 1 mg/kg three
times weekly for 25 weeks, INH-ODN-treated lupus mice sur-
vived longer than vehicle-treated controls (Figure 7a). INH-1-
treated, but not INH-18-treated, mice also showed less lym-
phadenomegaly (Figure 7b), less proteinuria (Figure 7c), and
decreased composite renal score (Figure 7d). As shown in
Figures 7e and 7f, INH-1-treated mice displayed less promi-
nent glomerular and peritubular IgG deposits. Furthermore,
palindromic class R INH-ODNs were more effective than linear
Figure 4
Higher potency of class R inhibitory oligonucleotides (INH-ODNs) for B-cell receptor-dependent activation of AM14 B cells induced with DNA-con- taining immune complexes Higher potency of class R inhibitory oligonucleotides (INH-ODNs) for B-cell receptor-dependent activation of AM14 B cells induced with DNA-con-
taining immune complexes. AM14 B cells were stimulated with (a) linear CpG-1826, (b) anti-nucleosome antibody PL2-3, or (c) lipopolysaccharide 
(LPS), and class R and class B INH-ODNs were added simultaneously. Proliferation of AM14 B cells was determined by measuring the [3H] thymi-
dine incorporation for the last 6 hours. Results are expressed as percentage of maximal stimulation induced with the particular Toll-like receptor lig-
and (n = 3). *P < 0.05 (INH-1 versus INH-18). **P < 0.05 (INH-1 versus control).
Figure 5
Both classes of inhibitory oligonucleotides (INH-ODNs) require CCT  and GGG triplets for the full inhibitory activity Both classes of inhibitory oligonucleotides (INH-ODNs) require CCT 
and GGG triplets for the full inhibitory activity. AM14 B cells were stim-
ulated with PL2-3 immune complexes. Indicated INH-ODNs and con-
trol ODN-4173 (all at a concentration of 1 μg/mL) were added 
simultaneously. Proliferation was measured. One of two similar experi-
ments is shown.Arthritis Research & Therapy    Vol 11 No 3    Lenert et al.
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class B INH-ODNs as inhibitors of both anti-dsDNA antibody
secretion (detected by immunofluorescence and by ELISA)
and of anti-Sm/RNP antibody secretion (as detected by
ELISA) (Figure 8).
Discussion
It was first observed by Pisetsky and his group [51,52] that
several G-rich ODNs made with the PS, but not PO, backbone
had inhibitory activity. We and others [39,40,53-61] have
extended these early observations to define structural require-
ments for TLR9 stimulation and inhibition in the nanomolar
range. Strikingly, changes at the 5' end of an ODN (either
inhibitory or stimulatory), particularly those affecting the pyrimi-
dine-rich CCT triplet, diminished both the stimulatory and
inhibitory activity for the TLR9 pathway [39,62]. We have also
identified a stretch of three (four) consecutive Gs necessary
for optimal inhibition in the nanomolar range [39,40,63].
Could DNA-like therapeutics offer a pathway-specific tool for
treating systemic lupus? Variants of our prototypic INH-ODN
2114 (TCCTGGAGGGGAAGT) [44,64] have already been
tested in lupus-prone animals. For example, Patole and col-
leagues [36] found that INH-ODN 2114 was active in the
MRL-lpr/lpr strain, whereas Klinman's group [35] discovered
that an ODN containing multiple TTAGGG repeats, like those
in telomeric DNA, was inhibitory in lupus-prone NZB/NZW F1
mice. Barrat and colleagues [37] recently obtained similar
results in the NZB/W-F1 strain, with an INH-ODN that com-
Figure 6
Class R and B inhibitory oligonucleotides (INH-ODNs) inhibit Toll-like receptor-7 (TLR7)-dependent activation of macrophages, dendritic cells  (DCs), AM14 B cells, and primary mouse B cells in a sequence-independent but backbone-dependent manner Class R and B inhibitory oligonucleotides (INH-ODNs) inhibit Toll-like receptor-7 (TLR7)-dependent activation of macrophages, dendritic cells 
(DCs), AM14 B cells, and primary mouse B cells in a sequence-independent but backbone-dependent manner. RAW264.7 macrophages (a, b), Flt-
3L-propagated bone marrow-derived DCs (c), AM14 B cells (d), and primary mouse resting B cells (e) were stimulated with TLR7/8 ligands (CL-
075, R-837, or RNA immune complexes as indicated) with INH-ODNs or control ODNs added simultaneously. Tumor necrosis factor-alpha (TNF-α) 
and interferon-alpha (IFN-α) were measured in enzyme-linked immunosorbent assay. AM14 proliferation was determined by measuring the [3H] thy-
midine incorporation for the last 6 hours. CD86 expression was determined by flow cytometry (n = 3 to 5). *P < 0.05 (ODN-treated versus medium-
treated samples). FITC, fluorescein isothiocyanate.Available online http://arthritis-research.com/content/11/3/R79
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bined the canonical TLR9-inhibitory motif with a TLR7-specific
TGC triplet at the 5' end. One dsDNA-based biocompound
LJP 394 (Abetimus) developed by the La Jolla Pharmaceutical
Company (San Diego, CA, USA) has already entered clinical
trials in human lupus and showed some promising results (for
example, ability to decrease anti-dsDNA antibody production
in vivo) [65].
The current report addresses the relevance of secondary
structure to INH-ODN activity. We created class R INH-ODNs
by starting with the shortest strongly active 12-mer linear INH-
ODN 4084-F (CCTGGATGGGAA) (Table 1) and then
extending it with 12 more bases, resulting in complete palin-
dromes (class R) or in non-palindromic linear sequences
(class B). Class R INH-ODNs were between 10- to 30-fold
less potent as inhibitors in resting mouse B cells than class B
INH-ODNs when synthetic linear TLR9 agonists were used for
Figure 7
Inhibitory oligonucleotides (INH-ODNs) prolong survival and decrease morbidity in MRL-Faslpr/lpr mice in vivo Inhibitory oligonucleotides (INH-ODNs) prolong survival and decrease morbidity in MRL-Faslpr/lpr mice in vivo. Pre-diseased MRL-Faslpr/lpr (2J strain) 
mice were treated with INH-1, INH-18, or vehicle starting from week 15 for 25 consecutive weeks. ODNs were injected intraperitoneally three times 
weekly at the concentration of 1 mg/kg body weight. Surviving mice were sacrificed at week 40. Similar results were obtained in three additional 
cohorts of lupus mice (J and 2J strains). Effects of INH-ODNs on survival (a), total lymph node weight (b), proteinuria (c), composite renal score (d), 
and IgG deposits in kidneys (e, f) are shown. *P < 0.05 (ODN-treated versus vehicle-treated). PBS, phosphate-buffered saline.Arthritis Research & Therapy    Vol 11 No 3    Lenert et al.
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stimulation (Figure 2). Similar findings were obtained in human
primary B cells/B-cell lines. In contrast to resting B cells, when
'professional antigen-presenting cells' (for example, primary
macrophages and bone marrow-derived DCs) were stimu-
lated either with complex CpG-class A(D) ODNs or with DNA-
containing immune complexes, classes R and B INH-ODNs
showed very similar inhibitory potencies (Figure 1). Stimulation
with these complex TLR9 ligands is believed to occur in DCs
in an early endosomal compartment [7,8].
This difference in inhibitory activity between class B and class
R INH-ODNs in resting (follicular) B cells was clearly depend-
ent on the ability of INH-ODNs to make double-stranded sec-
ondary structures. The biggest decrease in potency was
observed with class R INH-ODNs containing either complete
palindromes or short (up to three nucleotides) single-stranded
5' or 3' linear overhangs (Figure 3). Further increase in the
length of the single-stranded overhang progressively reduced
the difference between linear and class R INH-ODNs.
These results suggest a hypothesis that, in B cells (though not
in macrophages), dsDNA (including class R INH-ODNs) has
limited access to endosomal TLR9 relative to single-stranded
DNA. Single-stranded CpG-ODNs have been shown to
encounter TLR9 in LAMP-1-positive endosomes [8,9]. We
postulated that, if dsDNA gains access to these endosomes
by BCR-mediated entry, the difference in potencies between
double-stranded and single-stranded versions of the same
inhibitory sequence would disappear. This hypothesis could
be tested in transgenic B cells expressing a BCR either for
dsDNA or for Ig by stimulating the cells with one or both of
these components.
Thus, important proofs of concept emerged from studies in
AM14 B cells (Figures 7 and 8). These rheumatoid factor-spe-
cific B cells express a transgenic BCR derived from hybrid-
oma-secreting anti-Ig-specific autoantibodies [43]. Their BCR
recognizes the Fc-fragment of IgG2a antibodies expressing 'a'
but not 'b' allotype [25]. In vitro, AM14 B cells proliferate when
Figure 8
Class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantibody secretion in MRL-Faslpr/lpr mice in vivo Class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantibody secretion in MRL-Faslpr/lpr mice in vivo. Pre-diseased MRL-Faslpr/lpr 
mice were treated with INH-1, INH-18, or vehicle for 25 weeks as in Figure 7. Surviving mice were sacrificed and their sera tested for autoantibod-
ies. (a) The presence of anti-double-stranded DNA (anti-dsDNA) antibodies binding native DNA was determined semi-quantitatively by staining the 
Crithidia lucillae kinetoplasts. (b) The concentrations of anti-DNA and anti-Sm/RNP antibodies were further measured in enzyme-linked immuno-
sorbent assay. *P < 0.05 (ODN-treated versus vehicle-treated). PBS, phosphate-buffered saline.Available online http://arthritis-research.com/content/11/3/R79
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anti-nucleosome antibodies (PL2-3) are added to spent cul-
tures (Figure 4). This proliferation is sensitive to DNAse treat-
ment and requires an intact MyD88/TLR9 pathway [25,34],
clearly arguing for a role of endogenous DNA in PL2-3-
induced AM14 B-cell activation. Similar to other TLR9-
expressing cells, AM14 B cells proliferate vigorously to stimu-
lation with linear CpG ligands (Figure 4a).
These results suggest that PL2-3 binds nucleosome-associ-
ated chromatin released into the cultures from dying cells and
that these immune complexes engage the anti-Ig BCR, deliver
'signal 1', and enter the cell [25]. The dsDNA they contain then
reaches TLR9 in the endosome ('autophagosomes' [18]), oth-
erwise accessible only to single-stranded DNA. Therefore,
AM14 B cells represent an excellent model that can be used
to contrast data obtained through BCR-dependent and BCR-
independent TLR9-mediated signaling and to test some pre-
dictions of this hypothesis. As in non-autoreactive B cells, our
results show that 'BCR-independent' stimulation with linear
CpG-ODN 1826 was differentially inhibited by class R and
class B INH-ODNs, with class B 10-fold more potent than
class R (Figure 4a). However, in 'BCR-dependent' immune
complex-induced B-cell proliferation, classes B and R INH-
ODNs showed similar potencies for inhibition, primarily
because of the increased potency of class R INH-ODNs for
BCR-mediated activation (Figure 4b).
While the exact mechanism of class R INH-ODNs action in
autoreactive B cells remains to be determined, several possi-
bilities may be considered: (a) competition between TLR9-
inhibiting ODNs and endogenous DNA for binding to PL2-3
antibodies/nucleosome/HMGB1 complex, (b) competition for
binding to membrane RAGE (receptor for advanced glycation
endproducts)/BCR complex, (c) preferential recruitment of
TLR9 into early versus late endosomes depending on the
nature of the TLR9 ligand used, (d) BCR-dependent increase
in passive endocytosis of class R INH-ODNs, and (e) BCR-
dependent recruitment of specific helicases (DNA-unzipping
enzymes) into an early endosomal compartment. These possi-
bilities are not mutually exclusive. For example, inhibition of
BCR signaling might result from both better uptake/trafficking
of class R INH-ODNs into endosomes and better recruitment
of helicases into TLR9-containing compartments. Helicases
must have an important role in the class R INH-ODN-mediated
inhibition because recent affinity studies revealed superior
binding of single-stranded TLR9 ligands to chip-immobilized
TLR9 [3], an event that may depend heavily on the sugar back-
bone of the TLR9 ligands used for stimulation [4].
Another possibility is a direct competition between endog-
enous DNA and INH-ODNs for binding to anti-dsDNA anti-
bodies. While this possibility may account for some
competition observed in the PL2-3 model, there are no data in
the literature to suggest that natural anti-dsDNA antibodies (or
anti-chromatin antibodies) preferentially bind DNA segments
carrying the canonical inhibitory motif over other DNA
sequences [33].
The possibility that the double-stranded structure of class R
INH-ODNs may direct these ODNs preferentially to an early
endosomal compartment in macrophages and DCs and into
BCR-related 'autophagosomes' in autoreactive B cells has a
precedent in a work by Guiducci and colleagues [8]. These
authors have found that IFN-α secretion from human plasma-
cytoid DCs induced by multimeric class A(D) CpG-ODNs
occurs in transferring receptor-positive endosomes whereas
linear monomeric CpG-ODNs (like CpG-1826 used in our
experiments) preferentially localize to LAMP-1-positive endo-
somes and are poor stimulators of IFN-α secretion. However,
when linear CpG ligands are complexed into microparticles,
they now gain the ability to move to transferrin receptor-posi-
tive endosomes, inducing robust IFN-α production. Therefore,
the most important determinant of TLR9 signaling may be its
endosomal localization [7,8] or alternatively CXCL16 engage-
ment as suggested by the Klinman's group [9]. For one or
more of these reasons, class R INH-ODNs have higher
potency for BCR-dependent TLR9 activation in autoreactive B
cells than for BCR-independent activation of normal B cells.
In this article, we further question the ability of 'TLR9-specific'
INH-ODNs to target additional TLR signaling pathways. While
our previous data [44] and data from several other groups
[60,61] have clearly identified that INH-ODNs at concentra-
tions of up to 1 μM fail to inhibit signaling through the TLR2, 3,
and 4 pathways, recent literature has suggested a possibility
that PS-ODNs, including INH-ODNs, may also block the TLR7
signaling pathway [28]. It is believed that, in mice (in contrast
to humans), the TLR8 pathway is non-functional since cells
from TLR7-/- mice fail to respond to stimulation with synthetic
TLR7/8 ligands [2]. Here, we show that our INH-ODNs can
block TLR7-dependent activation of primary macrophages,
macrophage cell lines, RNA immune complex-activated DCs,
and AM14 B cells in a dose-dependent but sequence-inde-
pendent manner (Figure 6a–d). However, in spite of these
sequence-independent inhibitory effects, palindromic INH-
ODNs still have lower potency for resting B cells (Figure 6e),
but classes B and R are equally potent and effective in RNA/
anti-RNA-stimulated AM14 B cells (Figure 6d). Here again,
BCR engagement is associated with greater potency of class
R INH-ODNs.
Finally, in vivo, in the MRL-Faslpr/lpr strain, class R INH-ODNs
were better than class B INH-ODNs as inhibitors of both IgG
anti-dsDNA and anti-Sm/RNP antibody secretion (Figure 8).
These results may have significant impact for developing novel
DNA-like therapeutics for treating lupus. While TLR7-/- MRL-
Faslpr/lpr lupus mice have better survival, they still succumb to
autoimmune disease [49], thus suggesting a possible role for
additional DNA/RNA-triggered intracellular signaling path-
ways (for example, DAI and RIG-I). Interestingly, in this strain,Arthritis Research & Therapy    Vol 11 No 3    Lenert et al.
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complete lack of TLR9 results in two opposite outcomes:
diminished anti-dsDNA secretion but increased anti-Sm/RNP
antibody production [49]. Moreover, the survival of these mice
is reduced, likely due to insufficient number/function of regula-
tory T cells [66]. One can wonder whether the ability of class
R INH-ODNs to block both TLR9 and TLR7 activation in auto-
reactive B cells may explain the beneficial effect of these INH-
ODNs on autoantibody secretion in vivo. The inferior efficacy
of more in vitro potent class B INH-ODNs in lupus mice came
as a surprise. While we lack a logical explanation for this result,
recent literature suggests that PS-ODNs (including TLR9-spe-
cific INH-ODNs) may redirect TLR7/8 ligand-induced activa-
tion away from the TLR7 toward the TLR8 pathway, as
observed in HEK cells expressing TLR7 and TLR8 and in pri-
mary human peripheral blood mononuclear cells [67] and
mouse cells [68]. This redirection of TLR activation may result
in decreased IFN-α secretion from plasmacytoid DCs but a
corresponding increase in IL-12, TNF-α, and IFN-γ secretion
resulting from TLR8-expressing cells (for example, human
monocytes) [67].
Future studies should explore the efficacy of class R INH-
ODNs in different strains of lupus mice, including the BXSB
male mice. This lupus strain harbors a duplication of the TLR7
gene which appears to be responsible for the phenotype
[47,48]. Moreover, refinement of the palindromic structure to
generate combined selective TLR7/TLR9 inhibitors [37]
together with anti-B-cell-depleting protocols [23] to re-estab-
lish critical B-cell differentiation checkpoints [69] may result in
better treatments for human lupus.
Conclusions
Class R INH-ODNs have a high potency for autoreactive B
cells and DCs in vitro and are effective in the MRL-Faslpr/lpr
model of lupus in vivo.
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